CRP and neoplasm: If confirmed, the combination of neutrophil count and serum CRP (determined at any given time point prior to SARS‐CoV‐2 infection), could be employed as an easy‐to‐obtain biomarker to identify tumor patients at particular risk for a severe course of COVID‐19.